AB Science plummets as EU frowns on cancer drug

Damian Garde

France's AB watched its shares tank as much as 31% on Friday after a European Medicines Agency panel rejected its gastrointestinal treatment, casting serious doubts on the 's potential approval.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS